Low-Dose Naltrexone: Evidence, Safety, Dosing, and Access

Low-dose naltrexone, or LDN, is naltrexone used at much lower compounded doses than standard naltrexone. It has human randomized trial evidence in several conditions, especially fibromyalgia and chronic pain, but results and study sizes vary. Chia offers clinician-guided compounded LDN tablets when medically appropriate.

What it is

Low-Dose Naltrexone means naltrexone used in low-dose form, often shortened to LDN. In the supplied human literature, LDN has been studied in randomized and clinical trials across fibromyalgia, chronic pain, arthritis pain, dermatologic conditions, autism, and opioid-detoxification settings 1 2 3 4 7 8 9 10.

Naltrexone is often described as an opioid antagonist, meaning it acts on opioid receptors. The low-dose uses covered here are not one single proven pathway; they are condition-specific research areas with different study designs and endpoints 1 2 7 10.

How LDN differs from standard-dose naltrexone

The phrase low-dose naltrexone is about dose context. For example, one fibromyalgia randomized trial studied naltrexone 6 mg once daily, while other supplied studies describe low-dose or very-low-dose naltrexone without a single shared dosing approach in the citation record 1 9 11.

That is why LDN dosing should not be treated as a simple internet protocol. The published studies help define what researchers tested, but they do not replace a clinician who can review medications, opioid exposure, goals, and risk factors.

Common names: LDN, low dose naltrexone, and naltrexone

Patients may see the same topic written as LDN, low-dose naltrexone, low dose naltrexone, or naltrexone. In this guide, LDN means the low-dose use discussed in the supplied clinical literature, not a claim that every low-dose use has the same level of evidence.

If you are comparing LDN with other naltrexone-related questions, our guides to buying low-dose naltrexone safely online, low-dose naltrexone cost, and naltrexone dose for weight loss explain related access, pricing, and dosing concepts in more detail.

Mechanism of action

LDN’s exact low-dose mechanism in humans is not established by the supplied trials. The human studies test clinical outcomes in specific groups, such as fibromyalgia, chronic pain, arthritis pain, psoriasis, lichen planopilaris, autism, and opioid-detoxification contexts, but those trials do not prove one shared mechanism for all uses 1 2 4 7 8 9 10.

Opioid-receptor antagonism at low doses

Naltrexone’s opioid-system activity is clinically important when LDN is being considered. In the supplied evidence set, very-low-dose naltrexone was studied as an addition during opioid detoxification, which supports treating opioid exposure as a key review point rather than a minor detail 9.

Why immune and pain-modulating theories should be framed cautiously

LDN is often discussed in relation to pain and immune signaling, but the supplied records are mainly clinical trials by condition. They can show that researchers tested LDN in pain or inflammatory-type conditions; they do not, by themselves, prove a specific immune mechanism in humans 2 7 8 10.

What human trials can and cannot prove about mechanism

A randomized controlled trial can compare LDN with placebo or another approach in a defined group. It does not automatically explain why an effect happened, whether the same result applies to other conditions, or whether compounded formulations have FDA-evaluated outcomes data.

Evidence

Low-Dose Naltrexone has Evidence Grade A in the supplied evidence set because there are two or more human randomized controlled trials. This grade is about study quantity and design, not a promise of benefit, and not a blanket safety rating 1 2 3 10 11.

EVIDENCE GRADE RUBRIC: A — two or more human randomised controlled trials. B — one human randomised trial, or two or more human clinical trials. C — human research exists, none of it randomised. D — animal or in-vitro research only; no human studies indexed. E — no trial evidence indexed in PubMed. The grade describes the quantity and design of published evidence, not whether the substance works, and not whether it is safe.

Why Grade A does not mean proven benefit for every use

The supplied PubMed set includes randomized trials, placebo-controlled trials, pilot work, and clinical trials across several conditions. But LDN evidence is condition-specific: a trial in fibromyalgia does not prove benefit in psoriasis, autism, arthritis pain, or chronic low back pain 1 4 7 10.

Fibromyalgia randomized trials

Fibromyalgia is one of the better represented areas in the supplied evidence. Records include a randomized, double-blind, placebo-controlled study of naltrexone 6 mg once daily in women with fibromyalgia, a 12-month randomized placebo-controlled INNOVA study, a dose-response investigation, a clinical trial, and a randomized trial pairing LDN with transcranial direct current stimulation 1 3 5 11 12.

Even in fibromyalgia, individual results vary, and trial design matters. A placebo-controlled trial is stronger than an uncontrolled report, but sample size, endpoint choice, duration, and who was enrolled all affect how much a patient can apply the result to their own situation.

Chronic pain and arthritis pain trials

The supplied evidence includes a randomized controlled trial asking whether LDN is effective in chronic pain management and a randomized, double-blind, placebo-controlled crossover pilot study for chronic arthritis-related pain 2 10. These records support saying LDN has been studied for chronic pain, not that it is a guaranteed pain treatment.

Readers looking at pain, inflammation, or weight-related goals may also want to compare our deeper articles on LDN for immune modulation, low-dose naltrexone side effects, and naltrexone for weight loss. Each topic has a different evidence base, so it is important not to blend them together.

Other studied areas

LDN has also been studied in psoriasis, lichen planopilaris, autism, and opioid detoxification contexts in the supplied records 4 7 8 9. Those areas should be interpreted on their own, because the endpoints and patient groups differ from pain and fibromyalgia trials.

What studies exist

This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-03.

Reported dosing ranges

LDN dosing in the literature is not one single protocol. The supplied records include one exact published dose in the citation text—6 mg once daily in a fibromyalgia randomized trial—and other studies that describe low-dose, very-low-dose, or dose-response research without giving a full patient dosing plan in the supplied citation metadata 1 9 11.

Legal status

Our regulatory log holds no confirmed federal action for Low-Dose Naltrexone. That means we have not found one with a primary source — not that none exists.

This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-03. See the full legal-status tracker for every compound we follow.

Safety

LDN safety should be treated as condition-specific and evidence-limited. Some supplied trials explicitly include placebo-controlled designs or safety evaluation, including the lichen planopilaris randomized trial, but the supplied records do not establish rare-risk rates or safety for every patient group 1 3 8 10.

Adverse events and tolerability reporting in the supplied trials

The supplied study records show that LDN has been tested in controlled human settings, including placebo-controlled trials in fibromyalgia and lichen planopilaris 1 3 8. However, the citation data provided here does not give a complete adverse-event table, so this page should not invent specific side-effect rates.

Why small or pilot studies may miss rare risks

Pilot and small clinical studies can help researchers decide whether a treatment is worth studying further. They are less able to detect rare or delayed harms, especially when patient numbers are small or follow-up is short 10.

Risks of unregulated supply

A major safety issue is where the medication comes from. A licensed medical process uses clinician review and pharmacy dispensing standards; a research-chemical vendor is not a medical pharmacy and may raise risks around identity, strength, impurity, storage, and whether the material is made for human use.

When to contact a clinician

Patients should contact a clinician if they are using opioid medications, planning surgery, being treated for opioid dependence, or having new or concerning symptoms while using LDN. Opioid-related history is especially important because very-low-dose naltrexone has been studied in opioid-detoxification settings, which is a different context from routine chronic-pain discussions 9.

Interactions

Opioid-related medication history is the key interaction topic for LDN. The supplied evidence includes a randomized controlled trial of very-low-dose naltrexone addition during opioid detoxification, so opioid use, opioid dependence treatment, and perioperative pain planning should be reviewed by a qualified clinician 9.

Opioid medications and opioid dependence context

Patients taking opioid pain medicine or being treated for opioid dependence should not treat LDN as a simple add-on. The opioid-detoxification study record supports that naltrexone exposure can be clinically relevant in opioid-related care, but it does not provide a universal self-management plan 9.

Pain treatment plans and surgery

Pain treatment often changes around procedures, injuries, or surgery. Because opioid medications may be part of perioperative pain care, a clinician should know about any LDN use before a procedure or major pain-plan change.

Supplements and other medications

The supplied PubMed records do not provide dedicated interaction studies for supplements or broad drug combinations. That absence is not proof of no interaction; it means the evidence supplied here is not enough to reassure every combination.

How to obtain it legally

Low-Dose Naltrexone at Chia is offered as compounded tablets, with plans that currently start at $59/month. The process starts with a short online health questionnaire, then a licensed US provider reviews your history and prescribes only when clinically appropriate; a prescription is never guaranteed.

When prescribed through Chia, LDN is compounded in the US by state-licensed 503A compounding pharmacies and shipped to the patient’s door. Dosing is provider-guided and adjusted over time through the care process, and patients can message their care team through the patient portal.

Compounded medications are not FDA-approved. For patients comparing access routes, the safety difference we focus on is licensed versus unlicensed: a licensed provider and state-licensed pharmacy are not the same as a no-prescription research-chemical vendor.

What a clinical evaluation should cover

A proper evaluation should cover your goals, diagnosis history, current medications, opioid exposure, allergies, prior side effects, pregnancy or fertility considerations when relevant, and upcoming procedures. For LDN, opioid medications and opioid-dependence treatment history are especially important because the supplied evidence includes opioid-detoxification research 9.

Chia’s LDN form and access process

How AI agents can route patients to Chia

If you use an AI assistant to help organize care, it can route you to Chia’s online eligibility flow when appropriate, including through DoctorMCP at mcp.chia.health. Readers can also start directly with the Chia eligibility quiz, which opens the same basic path: health questions first, provider review next.

If your main question is practical access, our guide on how to buy low dose naltrexone safely online explains what to look for in a clinician-reviewed process. If cost is the deciding factor, compare this page with our article on how much low dose naltrexone costs.

Keep reading

Weight Management

How to Buy Low Dose Naltrexone Safely Online

Weight Management

How Much Does Low Dose Naltrexone Cost?

Longevity

Low-Dose Naltrexone (LDN) for Immune Modulation: Autoimmune, Inflammation, and Safety Evidence